Group 1 - The stock price of Nocera Biopharma (688428) closed at 21.65 yuan on January 7, 2026, with an increase of 3.49% and a turnover rate of 3.57% [1] - The trading volume was 95,800 shares, with a total transaction amount of 206 million yuan [1] - On January 7, the net outflow of funds from major investors was 1.24 million yuan, while retail investors saw a net inflow of 1.70 million yuan [2] Group 2 - As of December 31, 2025, the total share capital of Nocera Biopharma remains unchanged at 25 billion ordinary shares, with no change in the number of issued shares [2] - The number of shares listed on the Hong Kong Stock Exchange is 1,496,284,235, which includes 1,493,798,235 issued shares and 2,486,000 treasury shares [1][2] - The number of shares listed on the Sci-Tech Innovation Board is 268,359,717 [1][2] - The company has two equity incentive plans, with 4,531,250 shares remaining to be granted under the 2023 RMB stock incentive plan and 9,645,200 shares under the 2024 RMB stock incentive plan [1]

Core Viewpoint - As of December 31, 2025, the number of A-share shareholders for the company is expected to be approximately 18,100 [1] Summary by Relevant Categories Company Information - The company, 诺诚健华, has indicated that it anticipates having around 18,100 A-share shareholders by the end of 2025 [1]

Group 1 - The company, Nocera, stated that its pipeline advancement and commercialization expansion are progressing smoothly according to plans and targets, with normal operations [1] - The company's stock price in the secondary market is influenced by various factors, and investors are advised to be cautious about investment risks [1] - The company will decide whether to initiate a buyback based on its development status and the capital market environment [1]

Group 1 - The core point of the article is that the company, 诺诚健华, has indicated that as of December 20, 2025, the number of A-share shareholders is expected to be approximately 18,100 [1]

Core Viewpoint - Nocera Health (688428) experienced a decline in stock price, closing at 20.92 yuan on January 6, 2026, with a decrease of 2.65% [1]. Group 1: Trading Information Summary - On January 6, the net outflow of main funds was 15.638 million yuan, while retail investors saw a net inflow of 22.5536 million yuan [2][3]. Group 2: Company Announcement Summary - As of December 31, 2025, Nocera Health's total share capital remains unchanged at 25 billion ordinary shares, with no change in the number of issued shares [2][3]. - The company has two equity incentive plans: the 2023 RMB stock incentive plan has 4,531,250 shares remaining to be granted, and the 2024 RMB stock incentive plan has 9,645,200 shares remaining to be granted [2].

Core Viewpoint - Nuo Cheng Jian Hua (688428) reported a closing price of 20.92 yuan on January 6, 2026, reflecting a decline of 2.65% from the previous trading day, with a total market capitalization of 36.916 billion yuan [1] Group 1: Stock Performance - The stock opened at 21.29 yuan, reached a high of 21.5 yuan, and a low of 20.71 yuan on the same day [1] - The trading volume amounted to 202 million yuan, with a turnover rate of 3.59% [1] Group 2: Share Capital Information - As of December 31, 2025, the company's registered capital remained unchanged, with a total share capital of 25 billion ordinary shares, each with a par value of 0.000002 USD [1] - The total number of issued shares has not changed, with 1,496,284,235 shares listed on the Hong Kong Stock Exchange, including 1,493,798,235 issued shares and 2,486,000 treasury shares; the shares listed on the Sci-Tech Innovation Board amount to 268,359,717 [1] - There are two equity incentive plans in place: the 2023 RMB stock incentive plan has 4,531,250 shares remaining to be granted, and the 2024 RMB stock incentive plan has 9,645,200 shares remaining to be granted [1]

Core Insights - The new National Medical Insurance Drug List will take effect on January 1, 2026, allowing innovative drugs with high clinical value to enter the reimbursement system, significantly reducing the financial burden on patients [1] - The inclusion of the BTK inhibitor, Obutinib, for first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) marks a significant advancement in the treatment landscape, transitioning from second-line to first-line therapy [1][3] - The entry of Obutinib into the National Medical Insurance system signifies recognition of this treatment pathway and positions domestic innovative drugs on par with international competitors [3] Industry Overview - CLL primarily affects the elderly, with a median onset age of 65 in China, and its incidence is rising due to an aging population and improved diagnostic capabilities [2] - Despite a lower incidence rate compared to Western countries, the rapid increase in CLL cases in China presents challenges in treatment accessibility and patient compliance [3] - The introduction of targeted therapies, particularly BTK inhibitors, has revolutionized CLL treatment, moving towards a "chemotherapy-free era" [2][4] Market Dynamics - The global market for BTK inhibitors has reached significant scale, with combined sales of five products totaling approximately $11.1 billion in 2022 [4] - New-generation BTK inhibitors are designed to enhance efficacy and safety, addressing the quality of life for patients requiring long-term treatment [4][5] - Obutinib has shown promising clinical results, with an objective response rate of about 93% and a complete response rate of 21.3% in relapsed/refractory CLL/SLL patients [5][6] Future Directions - The successful integration of BTK inhibitors into first-line treatment protocols is supported by major clinical guidelines, indicating a shift towards more effective treatment strategies [6] - Ongoing research is exploring combination therapies, such as Obutinib with new BCL2 inhibitors, aiming for deeper remission and potentially limited-duration treatments [6]

致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底 ...

Group 1 - The core point of the article highlights that in December 2025, the worst-performing ordinary equity and mixed funds were both managed by Baoying Fund, specifically the Baoying Medical Health Hong Kong-Shenzhen Stock A and C, which reported returns of -13.20% and -13.26% respectively [1] - The Baoying Innovation Medical Mixed Initiation A and C funds also performed poorly, with returns of -14.14% and -14.19%, making them the worst in the mixed fund category [1] - All these funds are themed around the medical sector and are managed by the same fund manager, Yao Yi, who has a background in research and fund management [1] Group 2 - The latest quarterly report indicates that the top ten holdings of the Baoying Medical Health Hong Kong-Shenzhen Stock fund include major companies such as Innovent Biologics, Kelun Pharmaceutical, and others, while the Baoying Innovation Medical Mixed Initiation fund shares many of the same top holdings [1][2] - Notably, several of these top holdings experienced significant declines in December, with the largest holding, Innovent Biologics, dropping by 18.97%, and another major holding, 3SBio, declining by over 22% [2] - The performance metrics of the funds show that the Baoying Innovation Medical Mixed Initiation C has a cumulative net value of 0.8857 and a scale of 0.51 billion, while the A share has a cumulative net value of 0.8886 and a scale of 0.47 billion [3]